Cargando…
Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions
The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) triggered the pandemic of COVID-19, which is currently still ongoing. In 2021 a worldwide vaccine campaign was launched, and in parallel the lines of research are continuing to target the most effective drug therapies for the treat...
Autores principales: | Vitiello, Antonio, Zovi, Andrea, Trama, Ugo, Ferrara, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638345/ https://www.ncbi.nlm.nih.gov/pubmed/36331568 http://dx.doi.org/10.1007/s00059-022-05142-6 |
Ejemplares similares
-
Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection
por: Vitiello, Antonio, et al.
Publicado: (2022) -
Nirmatrelvir–remdesivir association for non-hospitalized adults with COVID-19, point of view
por: Ferrara, Francesco, et al.
Publicado: (2022) -
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment
por: Vitiello, Antonio, et al.
Publicado: (2022) -
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected
por: Ferrara, Francesco, et al.
Publicado: (2023) -
What Do We Know About the Smallpox Virus? A Journey Between Clinic and Therapy
por: Zovi, Andrea, et al.
Publicado: (2022)